Clinical isolates of ST131 < em > bla < /em > OXA-244-positive < em > Escherichia coli < /em > , Italy, December 2022 to July 2023
We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.PMID:38390649 | PMC:PMC10899817 | DOI:10.2807/1560-7917.ES.2024.29.8.2400073 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Aurora Piazza Marta Corbella Vittoria Mattioni Marchetti Cristina Merla Irene Mileto Angela Kuka Greta Petazzoni Stefano Gaiarsa Roberta Migliavacca Fausto Baldanti Patrizia Cambieri Source Type: research
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023
Euro Surveill. 2024 Feb;29(8):2300329. doi: 10.2807/1560-7917.ES.2023.29.8.2300329.ABSTRACTThe screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Nita Perumal Viktoria Sch önfeld Ole Wichmann Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | PMC:PMC10899815 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Authors' correction for Euro Surveill. 2024;29(3)
Euro Surveill. 2024 Feb;29(8):240222c. doi: 10.2807/1560-7917.ES.2024.29.8.240222c.NO ABSTRACTPMID:38390647 | PMC:PMC10899816 | DOI:10.2807/1560-7917.ES.2024.29.8.240222c (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.PMID:38390648 | PMC:PMC10899819 | DOI:10.2807/1560-7917.ES.2024.29.8.2300277 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Shogo Miyazawa Ting Sam Wong Genta Ito Ryo Iwamoto Kozo Watanabe Michiel van Boven Jacco Wallinga Fuminari Miura Source Type: research
Clinical isolates of ST131 < em > bla < /em > OXA-244-positive < em > Escherichia coli < /em > , Italy, December 2022 to July 2023
We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.PMID:38390649 | PMC:PMC10899817 | DOI:10.2807/1560-7917.ES.2024.29.8.2400073 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Aurora Piazza Marta Corbella Vittoria Mattioni Marchetti Cristina Merla Irene Mileto Angela Kuka Greta Petazzoni Stefano Gaiarsa Roberta Migliavacca Fausto Baldanti Patrizia Cambieri Source Type: research
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023
Euro Surveill. 2024 Feb;29(8):2300329. doi: 10.2807/1560-7917.ES.2023.29.8.2300329.ABSTRACTThe screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Nita Perumal Viktoria Sch önfeld Ole Wichmann Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | PMC:PMC10899815 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research
Authors' correction for Euro Surveill. 2024;29(3)
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.240222c.NO ABSTRACTPMID:38390647 | DOI:10.2807/1560-7917.ES.2024.29.8.240222c (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.PMID:38390648 | DOI:10.2807/1560-7917.ES.2024.29.8.2300277 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Shogo Miyazawa Ting Sam Wong Genta Ito Ryo Iwamoto Kozo Watanabe Michiel van Boven Jacco Wallinga Fuminari Miura Source Type: research
Clinical isolates of ST131 < em > bla < /em > OXA-244-positive < em > Escherichia coli < /em > , Italy, December 2022 to July 2023
We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.PMID:38390649 | DOI:10.2807/1560-7917.ES.2024.29.8.2400073 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Aurora Piazza Marta Corbella Vittoria Mattioni Marchetti Cristina Merla Irene Mileto Angela Kuka Greta Petazzoni Stefano Gaiarsa Roberta Migliavacca Fausto Baldanti Patrizia Cambieri Source Type: research
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2023.29.8.2300329.ABSTRACTThe screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Nita Perumal Viktoria Sch önfeld Ole Wichmann Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research
